HPTN 076

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP)

Sponsors:
Division of AIDS, US National Institute of Allergy and Infectious Diseases (NIAID)
US National Institutes of Health (NIH)

Protocol Summary:
HPTN 076 is a multi-site, double-blinded, two-arm study that will evaluate the safety and acceptability of the injectable product, TMC278 LA, in healthy, HIV-uninfected women. TMC278 LA is a long-acting formulation of the drug rilpivirine, which is a US-FDA approved medication used to treat HIV. This study will be an important step in determining if TMC278 LA can be administered as an injectable PrEP, and be studied further to see if it can prevent new HIV infections.

Years: 2015 – 2017

Investigators:
Nyaradzo Mgodi, MSc, MBChB, MMed
Z.M. Chirenje, MD, FRCOG

Location: Spilhaus CRS

HPTN

Completed Study

Publication:

Comments are closed.

Website by Canton Becker